AAPL343.01-0.90 (-0.26%) ▼|ABBV286.49-0.37 (-0.13%) ▼|ABT103.75-1.13 (-1.08%) ▼|ACN237.94-9.29 (-3.76%) ▼|ADBE251.84-6.78 (-2.62%) ▼|AMAT387.39-0.21 (-0.05%) ▼|AMD546.64+15.36 (+2.89%) ▲|AMGN445.45+0.82 (+0.18%) ▲|AMT187.21-1.08 (-0.57%) ▼|AMZN249.64+0.55 (+0.22%) ▲|AVGO337.32+8.15 (+2.48%) ▲|AXP313.64-1.41 (-0.45%) ▼|BA185.35-2.96 (-1.57%) ▼|BAC50.66+0.14 (+0.27%) ▲|BKNG151.00-2.14 (-1.40%) ▼|BLK1,131.08+3.42 (+0.30%) ▲|BMY61.33-0.28 (-0.45%) ▼|BNY147.54+0.36 (+0.24%) ▲|BRK-B544.92-3.64 (-0.66%) ▼|C122.83+1.79 (+1.48%) ▲|CAT703.11+10.98 (+1.59%) ▲|CL92.53-0.58 (-0.62%) ▼|CMCSA22.00-0.05 (-0.23%) ▼|COF202.51+0.16 (+0.08%) ▲|COP149.88-1.49 (-0.98%) ▼|COST997.30-7.86 (-0.78%) ▼|CRM242.68-4.93 (-1.99%) ▼|CSCO110.34+0.10 (+0.09%) ▲|CVS92.46-0.07 (-0.08%) ▼|CVX230.49-1.52 (-0.66%) ▼|DE650.76+9.51 (+1.48%) ▲|DHR231.87-1.10 (-0.47%) ▼|DIS109.83-0.57 (-0.52%) ▼|DUK124.33-0.11 (-0.09%) ▼|EMR163.10+1.40 (+0.87%) ▲|FDX304.14+3.56 (+1.18%) ▲|GD355.79-1.25 (-0.35%) ▼|GE293.40+4.97 (+1.72%) ▲|GEV874.06+19.44 (+2.27%) ▲|GILD157.38-1.31 (-0.83%) ▼|GM80.10+3.79 (+4.96%) ▲|GOOG314.70+0.51 (+0.16%) ▲|GOOGL318.22+1.42 (+0.45%) ▲|GS911.06+17.78 (+1.99%) ▲|HD317.96-1.43 (-0.45%) ▼|HON217.21-2.07 (-0.94%) ▼|IBM250.80-2.64 (-1.04%) ▼|INTC92.22+1.75 (+1.93%) ▲|INTU330.60-9.29 (-2.73%) ▼|ISRG449.42-2.21 (-0.49%) ▼|JNJ267.30+1.00 (+0.38%) ▲|JPM336.32+2.28 (+0.68%) ▲|KO92.66-0.04 (-0.04%) ▼|LIN507.34-0.22 (-0.04%) ▼|LLY1,286.81+7.67 (+0.60%) ▲|LMT631.64-3.56 (-0.56%) ▼|LOW196.11-2.12 (-1.07%) ▼|LRCX237.11-0.40 (-0.17%) ▼|MA607.87-5.63 (-0.92%) ▼|MCD248.95-1.88 (-0.75%) ▼|MDLZ62.44-0.53 (-0.84%) ▼|MDT94.11-0.68 (-0.72%) ▼|META621.64-8.92 (-1.41%) ▼|MMM172.09-0.70 (-0.41%) ▼|MO73.20-0.43 (-0.58%) ▼|MRK140.82+0.21 (+0.15%) ▲|MS186.22+2.73 (+1.49%) ▲|MSFT528.97-3.63 (-0.68%) ▼|MU914.58+10.88 (+1.20%) ▲|NEE82.20+0.16 (+0.20%) ▲|NFLX63.06-0.85 (-1.32%) ▼|NKE37.74-0.17 (-0.45%) ▼|NOW154.24-3.94 (-2.49%) ▼|NVDA215.85-0.15 (-0.07%) ▼|ORCL129.92+3.86 (+3.06%) ▲|PEP134.52-0.94 (-0.69%) ▼|PFE29.72-0.08 (-0.25%) ▼|PG159.07-0.86 (-0.53%) ▼|PLTR197.40-1.44 (-0.72%) ▼|PM203.35+1.48 (+0.73%) ▲|QCOM179.64+0.04 (+0.02%) ▲|RTX196.97-0.52 (-0.26%) ▼|SBUX101.44-1.26 (-1.22%) ▼|SCHW89.59-0.14 (-0.16%) ▼|SO91.96-0.62 (-0.66%) ▼|SPG211.59-1.10 (-0.52%) ▼|T20.95+0.10 (+0.46%) ▲|TMO688.36+3.47 (+0.51%) ▲|TMUS146.97+0.04 (+0.03%) ▲|TSLA401.33+9.71 (+2.48%) ▲|TXN302.37+4.25 (+1.43%) ▲|UBER65.67-0.46 (-0.70%) ▼|UNH411.41+0.71 (+0.17%) ▲|UNP296.79-0.18 (-0.06%) ▼|UPS103.16+2.84 (+2.83%) ▲|USB59.23-0.48 (-0.80%) ▼|V399.42-4.74 (-1.17%) ▼|VZ43.27+0.17 (+0.39%) ▲|WFC82.30-0.36 (-0.43%) ▼|WMT119.23-1.06 (-0.88%) ▼|XOM182.01-2.53 (-1.37%) ▼|AAPL343.01-0.90 (-0.26%) ▼|ABBV286.49-0.37 (-0.13%) ▼|ABT103.75-1.13 (-1.08%) ▼|ACN237.94-9.29 (-3.76%) ▼|ADBE251.84-6.78 (-2.62%) ▼|AMAT387.39-0.21 (-0.05%) ▼|AMD546.64+15.36 (+2.89%) ▲|AMGN445.45+0.82 (+0.18%) ▲|AMT187.21-1.08 (-0.57%) ▼|AMZN249.64+0.55 (+0.22%) ▲|AVGO337.32+8.15 (+2.48%) ▲|AXP313.64-1.41 (-0.45%) ▼|BA185.35-2.96 (-1.57%) ▼|BAC50.66+0.14 (+0.27%) ▲|BKNG151.00-2.14 (-1.40%) ▼|BLK1,131.08+3.42 (+0.30%) ▲|BMY61.33-0.28 (-0.45%) ▼|BNY147.54+0.36 (+0.24%) ▲|BRK-B544.92-3.64 (-0.66%) ▼|C122.83+1.79 (+1.48%) ▲|CAT703.11+10.98 (+1.59%) ▲|CL92.53-0.58 (-0.62%) ▼|CMCSA22.00-0.05 (-0.23%) ▼|COF202.51+0.16 (+0.08%) ▲|COP149.88-1.49 (-0.98%) ▼|COST997.30-7.86 (-0.78%) ▼|CRM242.68-4.93 (-1.99%) ▼|CSCO110.34+0.10 (+0.09%) ▲|CVS92.46-0.07 (-0.08%) ▼|CVX230.49-1.52 (-0.66%) ▼|DE650.76+9.51 (+1.48%) ▲|DHR231.87-1.10 (-0.47%) ▼|DIS109.83-0.57 (-0.52%) ▼|DUK124.33-0.11 (-0.09%) ▼|EMR163.10+1.40 (+0.87%) ▲|FDX304.14+3.56 (+1.18%) ▲|GD355.79-1.25 (-0.35%) ▼|GE293.40+4.97 (+1.72%) ▲|GEV874.06+19.44 (+2.27%) ▲|GILD157.38-1.31 (-0.83%) ▼|GM80.10+3.79 (+4.96%) ▲|GOOG314.70+0.51 (+0.16%) ▲|GOOGL318.22+1.42 (+0.45%) ▲|GS911.06+17.78 (+1.99%) ▲|HD317.96-1.43 (-0.45%) ▼|HON217.21-2.07 (-0.94%) ▼|IBM250.80-2.64 (-1.04%) ▼|INTC92.22+1.75 (+1.93%) ▲|INTU330.60-9.29 (-2.73%) ▼|ISRG449.42-2.21 (-0.49%) ▼|JNJ267.30+1.00 (+0.38%) ▲|JPM336.32+2.28 (+0.68%) ▲|KO92.66-0.04 (-0.04%) ▼|LIN507.34-0.22 (-0.04%) ▼|LLY1,286.81+7.67 (+0.60%) ▲|LMT631.64-3.56 (-0.56%) ▼|LOW196.11-2.12 (-1.07%) ▼|LRCX237.11-0.40 (-0.17%) ▼|MA607.87-5.63 (-0.92%) ▼|MCD248.95-1.88 (-0.75%) ▼|MDLZ62.44-0.53 (-0.84%) ▼|MDT94.11-0.68 (-0.72%) ▼|META621.64-8.92 (-1.41%) ▼|MMM172.09-0.70 (-0.41%) ▼|MO73.20-0.43 (-0.58%) ▼|MRK140.82+0.21 (+0.15%) ▲|MS186.22+2.73 (+1.49%) ▲|MSFT528.97-3.63 (-0.68%) ▼|MU914.58+10.88 (+1.20%) ▲|NEE82.20+0.16 (+0.20%) ▲|NFLX63.06-0.85 (-1.32%) ▼|NKE37.74-0.17 (-0.45%) ▼|NOW154.24-3.94 (-2.49%) ▼|NVDA215.85-0.15 (-0.07%) ▼|ORCL129.92+3.86 (+3.06%) ▲|PEP134.52-0.94 (-0.69%) ▼|PFE29.72-0.08 (-0.25%) ▼|PG159.07-0.86 (-0.53%) ▼|PLTR197.40-1.44 (-0.72%) ▼|PM203.35+1.48 (+0.73%) ▲|QCOM179.64+0.04 (+0.02%) ▲|RTX196.97-0.52 (-0.26%) ▼|SBUX101.44-1.26 (-1.22%) ▼|SCHW89.59-0.14 (-0.16%) ▼|SO91.96-0.62 (-0.66%) ▼|SPG211.59-1.10 (-0.52%) ▼|T20.95+0.10 (+0.46%) ▲|TMO688.36+3.47 (+0.51%) ▲|TMUS146.97+0.04 (+0.03%) ▲|TSLA401.33+9.71 (+2.48%) ▲|TXN302.37+4.25 (+1.43%) ▲|UBER65.67-0.46 (-0.70%) ▼|UNH411.41+0.71 (+0.17%) ▲|UNP296.79-0.18 (-0.06%) ▼|UPS103.16+2.84 (+2.83%) ▲|USB59.23-0.48 (-0.80%) ▼|V399.42-4.74 (-1.17%) ▼|VZ43.27+0.17 (+0.39%) ▲|WFC82.30-0.36 (-0.43%) ▼|WMT119.23-1.06 (-0.88%) ▼|XOM182.01-2.53 (-1.37%) ▼|
12.3 C
New York
Tuesday, October 27, 2026

Tag: inhibitors

newsFORsourcecompanycontentinformation1releasesmarket

Key Opinion Leader Event Highlights Pelareorep’s Compelling Pancreatic and Gastrointestinal Data And Future Potential

SAN DIEGO and CALGARY, AB, July 23, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for...

Key Opinion Leader Event Highlights Pelareorep’s Compelling Pancreatic and Gastrointestinal Data And Future Potential

SAN DIEGO and CALGARY, AB, July 23, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for...

Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening

Compounds developed through collaboration with Variational AI show targeted activity 
Compounds developed through collaboration with Variational AI show targeted activity

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

CLL Society Awards Research Projects Advancing CLL/SLL Care

2025 Research Program supports innovative studies aimed at improving outcomes and quality of life for CLL and SLL patients SAN DIEGO, July 21, 2025 /PRNewswire/...

Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed...

 

Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University...

TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1 billion (USD 7.3...

FSI ANNOUNCES SECOND QUARTER, 2025 REVENUE

TABER, ALBERTA, July 16, 2025 (GLOBE NEWSWIRE) -- FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE-AMERICAN: FSI), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. In addition, FSI is increasing its presense in the food and nutrition supplement manufacturing markets. Today the Company announces second quarter (Q2), 2025 revenue.

Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully...

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on...

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInhibitors

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers